时间标签：数据日期 2026-11-03 · 生成时间 2026-11-03 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31 – 2026/11/03 ｜ 情报发生日期 2026-11-03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
BACKGROUND: CRSwNP driven by type 2 inflammation is common across all ages, yet surgical outcomes in elderly patients remain poorly characterized. This study evaluated the safety and efficacy of ESS in patients aged ≥ 65 years with type 2 CRSwNP and compared outcomes with younger counterparts in the era of biologic therapy. METHODS: A retrospective cohort study was conducted at Tel Aviv Sourasky Medical Center, including 120 patients with type 2 CRSwNP who underwent ESS between January 2021 and December 2023. Patients were stratified into Group 0 (< 65 years, n = 94) and Group 1 (≥ 65 years, n = 26). Primary outcomes included postoperative complication rates and subjective improvement via SN…
对本项目的价值
参考价值：属「免疫衰老 / 炎症衰老」方向；其他衰老相关栏目可用作本项目文献库与综述素材。 ｜ 价值分 1.7/5（★★☆☆☆）
全文不可及原因
无 PMCID 且 OpenAlex / Unpaywall 未提供可下载 OA PDF
原文题录
- 中文题名：2 型慢性鼻窦炎伴鼻息肉术后年龄相关结局与生物制剂治疗需求
- 英文标题：Age-related outcome and biological treatment need after surgery for chronic rhinosinusitis with nasal polyposis type 2.
- 期刊与标识：Eur Arch Otorhinolaryngol · PMID 42966786 · DOI 10.1007/s00405-026-10774-z · EDAT 2026-11-01